Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017135540) TABLET CONTAINING TENELIGLIPTIN AND SULFONYLUREA-BASED DRUG
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/135540 International Application No.: PCT/KR2016/009576
Publication Date: 10.08.2017 International Filing Date: 29.08.2016
IPC:
A61K 9/20 (2006.01) ,A61K 9/14 (2006.01) ,A61K 47/26 (2006.01) ,A61K 47/36 (2006.01) ,A61K 31/497 (2006.01) ,A61K 31/17 (2006.01) ,A61K 31/18 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
14
Particulate form, e.g. powders
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
26
Carbohydrates
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
30
Macromolecular compounds
36
Polysaccharides; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4965
Non-condensed pyrazines
497
containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
17
having the group N-C(O)-N or N-C(S)-N, e.g. urea, thiourea, carmustine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
18
Sulfonamides
Applicants:
주식회사 한독 HANDOK INC. [KR/KR]; 서울시 강남구 테헤란로 132 132, Teheran-ro, Gangnam-gu, Seoul 06235, KR
Inventors:
한승진 HAN, Seungjin; KR
지은경 JI, Eunkyoung; KR
홍언표 HONG, Eonpyo; KR
류제필 RYOO, Jephil; KR
Agent:
특허법인 필앤온지 PHIL & ONZI INT'L PATENT & LAW FIRM; 서울시 서초구 서초중앙로 36, 3층 3F., 36 Seochojungang-ro Seocho-gu, Seoul 06643, KR
Priority Data:
10-2016-001220701.02.2016KR
Title (EN) TABLET CONTAINING TENELIGLIPTIN AND SULFONYLUREA-BASED DRUG
(FR) COMPRIMÉ CONTENANT DE LA TÉNÉLIGLIPTINE ET MÉDICAMENT À BASE DE SULFONYLURÉE
(KO) 테넬리글립틴 및 설포닐우레아계 약물을 포함하는 정제
Abstract:
(EN) The present invention relates to a complex tablet containing teneligliptin or a salt thereof and a sulfonylurea-based drug, wherein the complex tablet is prepared by mixing and tableting teneligliptin grains containing teneligliptin or a salt thereof and sulfonylurea-based grains containing a sulfonylurea-based drug. Preferably, both of the teneligliptin grains and sulfonylurea-based grains according to the present invention contain mannitol as a diluent. The complex tablet according to the present invention can effectively treat diabetic diseases by different mechanisms of teneligliptin and sulfonylurea, retains excellent stability due to a minimized interaction between drugs, and has excellent release patterns and absorption patterns. In addition, the complex tablet according to the present invention can reduce the absorption deviation between individuals and within individuals due to a reduced release deviation thereof.
(FR) La présente invention concerne un comprimé complexe contenant de la ténéligliptine ou un sel de celle-ci et un médicament à base de sulfonylurée, le comprimé complexe étant préparé par mélange et compression de grains de ténéligliptine contenant de la ténéligliptine ou un sel de celle-ci et des grains à base de sulfonylurée contenant un médicament à base de sulfonylurée. De préférence, les grains de ténéligliptine et les grains à base de sulfonylurée selon la présente invention contiennent tous deux du mannitol en tant que diluant. Le comprimé complexe selon la présente invention peut traiter efficacement des maladies diabétiques par des mécanismes différents de la ténéligliptine et d'une sulfonylurée, conserve une excellente stabilité en raison d'une interaction réduite au minimum entre les médicaments, et présente d'excellents profils de libération et profils d'absorption. De plus, le comprimé complexe selon la présente invention peut réduire l'écart d'absorption entre des individus et intra-individu en raison d'un écart de libération réduit de celui-ci.
(KO) 본 발명은 테넬리글립틴 또는 그의 염 및 설포닐우레아계 약물을 포함하는 복합 정제에 관한 것으로서, 테넬리글립틴 또는 그의 염을 포함하는 테넬리글립틴 과립 및 설포닐우레아계 약물을 포함하는 설포닐우레아계 과립을 혼합후에 타정하여 제조하는 것을 특징으로 한다. 바람직하게, 본 발명에 따른 상기 테넬리글립틴 과립 및 설포닐우레아계 과립 모두 부형제(diluent)로 만니톨을 포함한다. 본 발명에 따른 복합 정제는 테넬리글립틴 및 설포닐우레아의 서로 다른 메커니즘에 의해 당뇨 질환을 효과적으로 치료할 수 있을 뿐만 아니라 약물간 상호반응이 최소화되어 우수한 안정성을 가지며, 우수한 용출 패턴과 흡수 패턴을 가진다. 또한 본 발명에 따른 복합 정제는 용출 편차가 감소되어 개체간 및 개체내 흡수 편차를 줄일 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)